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term cost-effectiveness is evaluated using a 12-month treatment period with ti-
cagrelor versus clopidogrel in patients with ACS based on PLATO trial data from the
Mexican public and private perspective. METHODS: The cost-effectiveness model
is divided into two parts: a short-term decision tree based on data from the PLATO
trial to estimate rates of cardiovascular events, healthcare costs, and health-re-
lated quality of life for the 12 months of therapy and a long-term Markov model to
estimate quality-adjusted survival and costs conditional on whether a non-fatal
MI, a non-fatal stroke or no MI or stroke occurred during the 12 months of therapy.
Costs were calculated by applying 2010 Mexican unit costs. The daily drug price
used was $2.05 and $4.91 for clopidogrel and ticagrelor, respectively. The estimated
mean costs and QALYs are calculated over a lifetime time horizon and presented as
incremental cost per QALY. Probabilistic sensitivity analyses were performed.
RESULTS: Ticagrelor was associated with a QALY gain of 0.10; this was primarily
driven by lower mortality and fewer non fatal MI’s resulting in an incremental cost
per QALY gained of $7670 and $7073 for the public and private healthcare sector,
respectively. Probabilistic sensitivity analysis indicated that ticagrelor has more
than 99% probability of being more cost-effective than clopidogrel at a willingness
to pay of $30,000 per QALY. The results were consistent in all ACS subgroups.
CONCLUSIONS: Ticagrelor  aspirin is a cost effective treatment compared to
clopidogrel  aspirin for one year treatment in ACS patients based on the PLATO
trial and Mexican unit costs.
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Recently, ticagrelor showed a statistically significant absolute reduction (1.1%/
year) in cardiovascular (CV) mortality and in myocardial infarction (MI) (1.1%/year)
compared to clopidogrel in acute coronary syndrome (ACS) patients (from pub-
lished results of the PLATO trial). The majority of earlier ACS trials (including CURE
- placebo vs. clopidogrel and TRITON - clopidogrel vs. prasugrel) have not shown
this significant reduction in CV mortality. OBJECTIVES: To estimate the cost-effec-
tiveness of 1-year add-on therapy to aspirin with ticagrelor versus clopidogrel in
patients with ACS in the Dutch setting, based on the published results from PLATO.
METHODS: A published Markov cost-effectiveness model with MI, stroke, death
and subsequent events as health states is used to assess the cost-effectiveness of
ticagrelor in comparison to clopidogrel. In the model relevant utilities and costs are
linked to the health states. Short-term probabilities are based on the published
PLATO trial, while probabilities for subsequent events are assumed to change with
time and occurring events. Several sources were used for these extrapolations. The
cost-effectiveness was tested over daily acquisition cost of ticagrelor varying be-
tween €1 and €7 higher than clopidogrel. Relevant discount rates were applied and
probabilistic sensitivity analyses were conducted. RESULTS: Considering direct
medical costs only, the incremental cost-effectiveness ratios (ICERS) when the cost
of ticagrelor is assumed to be €1, €3, €5, and €7 higher than clopidogrel per day are
estimated at €3,742/QALY, €12,058/QALY, €20,374/QALY, and €28,691/QALY respec-
tively. Probabilistic sensitivity analyses show that ticagrelor is expected to be cost-
effective at a willingness to pay of €30,000 in 100.0%, 98.2%, 89.4%, and 58.0% of
cases when the price is assumed to be €1, €3, €5, or €7 higher than clopidogrel per
day, respectively. CONCLUSIONS: The reduction in mortality seen in the PLATO
trial translates to favorable cost-effectiveness results for ticagrelor, assuming the
price difference over clopidogrel does not exceed €7.50 per day.
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OBJECTIVES: The PLATO trial was a multicentre, double-blind, randomized trial
comparing clopidogrel  aspirin and ticagrelor  aspirin for treatment of patients
with ST-elevation and non-ST-elevation acute coronary syndromes (ACS). The re-
sults showed a significant reduction for ticagrelor in the primary composite end-
point – cardiovascular deaths, myocardial infarction, or stroke - without a signifi-
cant increase in major bleeding. Based on PLATO trial data long-term cost-
effectiveness was evaluated for 12-month treatment with ticagrelor versus
clopidogrel in patients with ACS, from the Brazilian public health care perspective.
METHODS: For the analysis of cost-effectiveness a two-part cost-effectiveness
model was used. The first part was a 12-month decision tree using PLATO trial data
to estimate rates of cardiovascular events, healthcare costs, and health-related
quality of life for the 12 months of therapy. The second part was a long-term
Markov model estimating quality-adjusted survival and costs conditional on
whether a non-fatal MI, a non-fatal stroke, or no MI or stroke occurred during the 12
months treatment. The model applied a lifetime horizon to calculate mean costs
and QALYs. The results are presented as incremental cost-effectiveness ratios (IC-
ER’s). Daily costs of $1.62 for generic clopidogrel and $4.58 for ticagrelor were ap-
plied. Other costs were calculated by applying Brazilian year 2010 unit costs. Prob-
abilistic sensitivity analysis was performed. RESULTS: Ticagrelor was associated
with a QALY gain of 0.10, primarily driven by lower cardiovascular mortality. The
resulting incremental cost per QALY gained was $8966 in the public sector. Proba-
bilistic sensitivity analysis indicated that ticagrelor had more than 99% probability
of being cost-effective at a willingness to pay of $30,000 per QALY. The results were
consistent in all analyzed subgroups. CONCLUSIONS: Based on the PLATO trial
data one year treatment with ticagrelor  aspirin versus clopidogrel  aspirin in
ACS patients is cost-effective from a Brazilian public health care perspective.
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OBJECTIVES: To evaluate the long term cost-effectiveness of rosuvastatin versus
generic atorvastatin in the treatment of patients at high cardiovascular risk (CVR)
5% SCORE or patients with established cardiovascular disease in Spain.METHODS:
The efficacy data from STELLAR trial (Statin Therapies for Elevated Lipid Levels
compared Across doses to Rosuvastatin) was used to simulate cLDL goal attain-
ment at different doses of rosuvastatin and generic atorvastatin during an initial
period of one year. These results were combined in the long term through a Markov
model which estimated the number of cardiovascular events and their impact on
quality of life in patients at high CVR using the Framingham risk equations. The
model estimated quality adjusted life years (QALY) and costs (drug and events
costs) up to 20 years. The analysis was conducted from the Spanish National Health
System perspective. 3% annual discount rate was applied to costs (€ 2010) and
outcomes. Cost-effectiveness was estimated in several subgroups of patients at
high CVR according to blood pressure, smoking status, age, cholesterol levels and
established cardiovascular disease. RESULTS: In primary prevention of cardiovas-
cular events in patients at high risk, rosuvastatin was a cost-effective option (cost/
QALY less than €30,000) versus generic atorvastatin in most of the subgroups ana-
lyzed. In patients with established cardiovascular disease, rosuvastatin was a cost-
effective option in all males subgroups (ICERs between €4,000 and €18,000 per
QALY) and in most of the females subgroups. CONCLUSIONS: The treatment of
patients at high cardiovascular risk with rosuvastatin was more effective than
generic atorvastatin in terms of survival and quality adjusted survival. Incremental
cost-effectiveness ratios were below the commonly accepted efficiency threshold
in Spain (€30,000) in most of the defined subpopulations by different combination
of risk factors.
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OBJECTIVES: 1) To estimate the time and cost of discharge for patients receiving
the current antithrombotic standard of care, warfarin / a heparin product at a
large US academic medical center, and 2) to estimate the system-level impact of a
hypothetical new oral antithrombotic in terms of improved discharge efficiency.
METHODS: Data were obtained from 2010 institutional metrics: patient volume,
major diagnoses (e.g., orthopedic surgery, atrial fibrillation), and resource require-
ments (time and cost of personnel providing antithrombotic discharge counseling;
time and cost of INR-related discharge delays). Metrics were coded as inputs in a
MS Excel model to estimate the potential time and cost impact of changes in pa-
tient volume, personnel providing counseling, or addition of novel oral agents to
the formulary. It was assumed that 80% of warfarin patients would receive the
novel antithrombotic, that these drugs would reduce discharge counseling time by
70%, and would not require INR testing. The cost per day of the new agent was
assumed to be $7 versus $0.82 for warfarin, and the bed of discharged patients was
assumed to be refilled with a new patient 100% of the time at a reimbursement rate
of $1500/day. RESULTS: Based on 1000 patients with a LOS of 4 days, efficiency
impacts of the new agent were estimated as follows: 4000 hours through avoidance
of INR-related delays, 400 hours through elimination of delayed discharge coun-
seling, 284 hours in reduced time to administer discharge counseling. Total patient
days saved by the new drug were 142 per year, translating to $213,000 in revenue
opportunity by improving the efficiency of the discharge process. Additional drug
costs to the facility were estimated to be $19,776 assuming drug prices and patient
volume are consistent with model inputs. CONCLUSIONS: The model quantifies
the system-level impact of new oral antithrombotics and informs formulary deci-
sion making.
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OBJECTIVES: To compare the efficiency of three strategies for the stenosis of the
femoropopliteal sector treatment: bypass surgery (BP), percutaneous transluminal
angioplasty with selective stent insertion (PTA/S), and percutaneous transluminal
angioplasty with selective stent insertion followed by possible bypass surgical re-
intervention (PTA/S/BP). METHODS: An economic evaluation was developed by
implementing a Markov model with three main branches representing each of the
strategies studied. We used a time horizon of 30 years, discounting 3% to costs and
effects. The measure of effectiveness was years of quality-adjusted life (QALYs).
Probabilistic and multivariate sensitivity analysis was performed by using Monte
Carlo (MC) methods. Acceptability curves and the expected value of perfect infor-
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